We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208

News   Oct 08, 2013

 
MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208
 
 
 

RELATED ARTICLES

Restricted Protein Diet Improves Immunotherapy Response in Mice

News

Restricting protein from a cancer patient's diet may enhance the response to immunotherapy.

READ MORE

Antibiotics Can Make Oral Infections Worse Rather than Better

News

The body’s own microbes are effective in maintaining immune cells and killing certain oral infections.

READ MORE

First Patient in the UK Receives Pioneering Form of Radiotherapy

News

The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, have delivered the first ever treatment in the UK using a Magnetic Resonance Linear Accelerator (MR Linac) machine.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE